SELLAS Life Sciences (SLS) Cash from Operations (2019 - 2024)
Historic Cash from Operations for SELLAS Life Sciences (SLS) over the last 9 years, with Q3 2024 value amounting to -$7.8 million.
- SELLAS Life Sciences' Cash from Operations fell 1326.18% to -$7.8 million in Q3 2024 from the same period last year, while for Sep 2024 it was -$33.1 million, marking a year-over-year decrease of 421.27%. This contributed to the annual value of -$35.4 million for FY2024, which is 1270.93% down from last year.
- As of Q3 2024, SELLAS Life Sciences' Cash from Operations stood at -$7.8 million, which was down 1326.18% from -$9.7 million recorded in Q2 2024.
- In the past 5 years, SELLAS Life Sciences' Cash from Operations ranged from a high of $3.4 million in Q4 2020 and a low of -$12.1 million during Q1 2023
- Over the past 5 years, SELLAS Life Sciences' median Cash from Operations value was -$5.9 million (recorded in 2021), while the average stood at -$6.3 million.
- Its Cash from Operations has fluctuated over the past 5 years, first plummeted by 24532.71% in 2021, then skyrocketed by 3037.3% in 2022.
- SELLAS Life Sciences' Cash from Operations (Quarter) stood at $3.4 million in 2020, then crashed by 245.33% to -$5.0 million in 2021, then fell by 3.54% to -$5.2 million in 2022, then increased by 6.35% to -$4.8 million in 2023, then plummeted by 61.78% to -$7.8 million in 2024.
- Its last three reported values are -$7.8 million in Q3 2024, -$9.7 million for Q2 2024, and -$10.8 million during Q1 2024.